Saba Capital Management’s enGene Therapeutics Warrants ENGNW Stock Holding History

Saba Capital Management’s Portfolio ENGNW Stock Details ENGNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$101K	Sell	40,057 -97,301	-71%	-$288K	﹤0.01%	278
2025 Q4	$391K	Sell	137,358 -40,976	-23%	-$93.5K	0.01%	218
2025 Q3	$128K	Hold	178,334	–	–	﹤0.01%	236
2025 Q2	$146K	Hold	178,334	–	–	﹤0.01%	222
2025 Q1	$111K	Hold	178,334	–	–	﹤0.01%	160
2024 Q4	$150K	Sell	178,334 -14,000	-7%	-$20.7K	﹤0.01%	159
2024 Q3	$274K	Hold	192,334	–	–	0.01%	175
2024 Q2	$248K	Sell	192,334 -1,629	-0.8%	-$5.21K	0.01%	190
2024 Q1	$1.01M	Sell	193,963 -36,507	-16%	-$111K	0.02%	166
2023 Q4	$271K	Buy	+230,470	New	+$177K	0.01%	265

Other funds holding ENGNW

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Blue Owl Capital Holdings New York $369M AUM 78.25% 1-Year Est. Return

LMR Partners London, United Kingdom $10.9B AUM 60.68% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.36B AUM 24.94% 1-Year Est. Return

D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return

Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return

CSS LLC Chicago, Illinois $1.8B AUM 59.56% 1-Year Est. Return

Ionic Capital Management New York $119M AUM 48.26% 1-Year Est. Return

Clear Street New York $17.8B AUM 56.26% 1-Year Est. Return